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To cause disease, bacterial pathogens must first
breach physical barriers, such as the mucous mem-
brane that lines organs, and then successfully repli-
cate and disseminate while avoiding destruction by
the immune system. Many bacterial pathogens
accomplish this by secreting proteins into their host
environment, which act to subvert or dampen the
expanding immune response. Here, we discuss how
bacterial pathogens use an arsenal of secreted
virulence proteins to modify the outcome of innate
immune activation by altering how the immune
system recognizes microbial invaders.
Introduction
Bacterial pathogens have evolved highly sophisticated
mechanisms to adapt to their host environment in
order to promote successful replication and dissemi-
nation. Bacterial subsistence in the context of the host
environment involves a complex interplay between
bacterial survival strategies and the ensuing host
response to infection, which in many cases serves to
limit the replication of the microorganism and prevent
its dissemination within the body and to new hosts.
The host response to infection begins with the identi-
fication of a foreign invader through the use of innate
immune surveillance systems, which alert the body to
an infection and induce a suite of inflammatory mol-
ecules that ultimately shape the adaptive arm of the
immune response. The importance of this central
defense mechanism — called innate immunity — is
exemplified by its presence in organisms across all
kingdoms, including insects, nematodes, plants, and
in more complex mammals where it serves as the
front-line defense against microorganisms before the
adaptive immune response is initiated [1,2]. 
The ability to detect, respond to, and destroy invad-
ing microbes is a central tenet for survival, and thus
forms a formidable barrier that successful pathogens
must overcome [3,4]. This is especially true of infect-
ing microbes that rapidly replicate and induce disease
symptoms that overwhelm the innate defenses of the
host and transmit to a new host before the adaptive
immune response can be activated, but is also neces-
sary for ‘stealth’ pathogens that replicate more slowly
and cause persistent infections by interfering with
both innate and adaptive immune pathways [5]. The
innate arm of the immune response is vigorous and
intuitive, responding to molecular signatures charac-
teristic of many pathogens, as opposed to unique
antigens that ultimately shape the exquisite specificity
and clonal nature of adaptive immunity.
In order to persist within and exploit their chosen
host in the face of a robust innate immune response,
bacterial pathogens often secrete virulence factors (or
effectors) into host cells or into the surrounding space
that in some way modify host biology to the benefit of
the pathogen. The host cell targets of secreted bacte-
rial proteins are diverse, including cytoskeletal com-
ponents, host cell receptors, an array of signaling
molecules, and other host proteins compartmental-
ized in various organelles. Intense research into this
area is beginning to elucidate the repertoire of effec-
tor targets, although the mechanism of their action is
often more elusive. The modification of host cell path-
ways allows incoming microbes to replicate in a
desired niche in the body, quite often inside host cells,
or sometimes on the surface of a host cell. This is the
first step in bacterial colonization and pathogenic
microbes must still overcome a large hurdle in order to
be successful — surviving, replicating and dissemi-
nating in the face of host immunity. 
In this review, we discuss how pathogenic bacteria
utilize secreted proteins to avoid recognition by the
innate immune system of the host and how, if recog-
nized, similar secreted proteins function to subvert or
dampen the expanding immune response. We have
emphasized the use of type III and type IV secretion
pathways because these secretion systems provide
direct conduits into the host cell where the translo-
cated effectors can directly modify immune effector
functions. We also examine innate immune pathways
for which little information is currently known and
which could be potential targets of translocated bac-
terial virulence factors.
Innate Immunity and the Weapons to Fight It
There are several strategies that microbes employ to
circumvent and overcome innate responses. Many
bacterial pathogens have evolved sophisticated
secretion systems to inject bacterial molecules into
animal and plant cells. These type III and type IV
secretion systems [6–10] are complex organelles that
span the Gram-negative envelope, and form a conduit
to deliver proteins (and, in the case of type IV systems,
DNA) into host cells. The general components of type
III and type IV secretion systems are usually con-
served, but the particular translocated effectors that
enter into host cells are often unique to particular
pathogens. The repertoire of effectors dictates the
choice of host, how the pathogen behaves inside that
host, and ultimately the disease. Many, but certainly
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not all, effectors are key virulence factors, that is, they
are required to cause disease. These effectors target
host cellular processes including those linked to
innate responses, disrupting or altering these path-
ways as part of the disease process. The cellular
targets are numerous, although those of choice are
often central regulators of essential processes, such
as cytoskeletal dynamics and vesicular trafficking.
Although currently the number of examples is limited,
it is possible that for most central cellular processes
there is at least one microbial pathogen that targets it.
In addition to the type III and IV systems, at least three
other secretion systems exist, including type I (signal-
sequence-independent pathway), type II (the terminal
step of a two-step secretion process) and type V
(autotransporter pathway) that serve to move various
protein substrates from inside bacteria to the extra-
cellular space (reviewed in [11–14]).
Picking a Niche and Sticking to It
Phagocytosis is an important innate defense mecha-
nism, a central event where innate and adaptive
immunity converge. Phagocytosis allows the internal-
ization and destruction of many pathogens by immune
cells, and is the essential prerequisite to processing
and presentation of microbial antigens for generation
of a specific, adaptive immune response [15]. Crucial
to these functions are phagocytic cells, or more
specifically professional antigen-presenting cells
(APCs) such as dendritic cells and macrophages.
These APCs are situated in peripheral and lymphoid
tissues and are able to recognize structural motifs and
nucleic acids that are conserved in micro-organisms
but are not present in higher eukaryotes. These motifs
are referred to as pathogen-associated molecular pat-
terns (PAMPs; see more below), the binding of which
to their corresponding pattern recognition receptors
(PRRs) leads to a cascade of signaling events pro-
moting the activation of innate and adaptive immune
responses [16]. Bacterial pathogens have evolved
strategies for dealing with the activities of phagocytes,
some by preventing uptake into these cells, and
others by actively invading APCs and establishing
intracellular residency.
The Outsider Strategy
Some bacterial pathogens use highly effective mech-
anisms to avoid phagocytic uptake into macrophages,
thereby avoiding robust microbicidal effector func-
tions [3]. For some bacterial pathogens such as
Yersinia sp., enteropathogenic Escherichia coli, and
Pseudomonas aeruginosa, this process of ‘antiphago-
cytosis’ is elicited by their type III secretion system,
which delivers bacterial proteins into the macrophage
cytosol to specifically impair the signaling down-
stream of phagocytic receptors (Figure 1). Enteropath-
ogenic E. coli inhibits phagocytosis into macrophages
by attenuating phosphatidylinositol (PI) 3-kinase acti-
vation shortly after bacterial contact with the host cell
surface [17]. This process occurs in wild-type bacte-
ria, but not in type III secretion mutants, although the
identity of the type III effector(s) responsible for this
activity remains to be identified. P. aeruginosa
secretes at least two exotoxins called ExoS [18] and
ExoT [19,20] through its type III secretion system.
These proteins have GTPase-activating activity
towards Rho-family GTPases, such as Rho, Rac1 and
Cdc42, and this prevents P. aeruginosa uptake by
both epithelial cells and macrophages. 
Yersinia use a more functionally overlapping set of
type-III-secreted virulence proteins to interfere with
phagocytosis, with at least three secreted effectors
Current Biology
R857
Figure 1. Pathogen modification of
phagocytosis.
Some pathogens such as Pseudomonas,
enteropathogenic E. coli (EPEC), and
Yersinia can block phagocytic uptake into
macrophages. By translocating specialized
type III effector proteins into the
macrophage cell, these pathogens inter-
rupt the signal transduction cascades nec-
essary for actin rearrangement and thereby
prevent phagocytosis. Other pathogens
that use a type IV secretion system (such
as Brucella and Legionella), or type III
secretion systems (such as Salmonella,
and probably Chlamydia), can induce their
own uptake into macrophages by stimulat-
ing actin rearrangements proximal to
attached bacteria, and then secrete addi-
tional effectors into the host cell to modify
the trafficking of the invasion vacuole in
order to prevent fusion with lysosomes.
Vacuoles containing Legionella and Bru-
cella, for example, then acquire markers of
the endoplasmic reticulum, thereby creat-
ing a protective niche for replication within




























targeting this process. YopH is a tyrosine phos-
phatase that de-phosphorylates cytoskeletal proteins
required for the formation of focal adhesions [21,22];
YopE is a GTPase-activating protein that prevents
actin polymerization; and YopT is a cysteine protease
that proteolytically cleaves Rho GTPases near their
carboxyl termini, releasing them from the membrane
[23]. These translocated effectors from Yersinia act in
concert to block the requisite actin rearrangements
and cytoskeletal changes needed for phagocytosis by
macrophages. Interestingly, YopT shares homology
with another type-III-secreted effector, AvrPphB, from
the phytopathogenic bacteria P. syringae. AvrPphB is
an avirulence protein that can trigger a disease-resis-
tance phenotype in several host plants including Ara-
bidopsis [23,24]. Because the downstream processes
subsequent to phagocytosis of bacterial pathogens by
macrophages — such as stimulation of pro-inflamma-
tory cytokines and chemokines, and processing of
bacterial antigens for presentation to the immune
system — are so instructive for the development of an
appropriate adaptive immune response, avoiding
phagocytosis into immune cells may also provide
these pathogens with a less hostile extracellular niche
that lacks humoral host defenses.
Taking the Inside Track
For intracellular bacteria whose pathogenicity relies
on invading and replicating within immune cells, these
bacteria face an even greater challenge in dealing with
the antimicrobial effector functions evolved to destroy
them. A common strategy employed by bacterial
pathogens that establish residency in eukaryotic host
cells is to modify the cytoskeleton of the host cell in a
way that promotes bacterial uptake at the cell surface
and then directs the early trafficking of the nascent
phagocytic vacuole (reviewed in [25–27]; Figure 1).
Once inside the host cell, some bacteria sequester
themselves in a membrane-bound vacuole that does
not fuse with lysosomes [26,28], and, in doing so,
create a replicative organelle in which to grow. 
The modification of vacuolar trafficking and the
acquisition of host-derived lipids and proteins have
been well-studied for the intracellular pathogen,
Legionella pneumophilia, which uses a type IV secre-
tion system to intercept vesicular traffic from endo-
plasmic reticulum (ER) exit sites [29,30]. The dot/icm
genes of Legionella encode a type IV protein secretion
apparatus that L. pneumophilia require for avoiding
the degradative function of the host lysosome and for
generating the replicative vacuole. One Legionella
protein that may play a role in this process is the type-
IV-secreted substrate called RalF [31], which interacts
with the host protein ADP ribosylation factor 1 (ARF1).
ARF1 is a small GTP-binding protein that regulates
vesicular traffic from the ER to the Golgi apparatus.
The RalF protein is required for the localization of ARF
on Legionella phagosomes, although it is not required
for the intracellular growth of Legionella in either
macrophages or the aquatic protozoan host Acan-
thamoeba castellanii [31]. Brucella also uses a type IV
secretion system to interact with the ER shortly after
invasion, and this is required for avoiding fusion with
lysosomes and for intracellular replication in
macrophages [32]. In other phagocytic cells, such as
dendritic cells, however, the formation of a modified
ER-like vacuole does not appear to totally restrict the
processing and presentation of bacterial antigens to
the immune system, at least during experimental
Legionella infection [33]. 
These data add important information about how
immune responses are generated against bacteria
that avoid being delivered to lysosomes. Furthermore,
the finding that the ER is a major reservoir of mem-
brane for phagosome formation and antigen presen-
tation [34,35] has important implications for how the
immune system deals with vacuolar pathogens such
as Legionella and Brucella, which associate with ER
components in order to furnish a more hospitable
phagosomal compartment. Lastly, other successful
intracellular bacteria such as Salmonella [36] and
Mycobacterium tuberculosis [37,38] have developed
sophisticated ways by which to modify the outcome
of phagocytic uptake by macrophages. These
pathogens are able to redirect phagocytic vesicle
traffic away from the degradative function of host
lysosomes and modify the acidification of the vacuo-
lar lumen in ways that promote activation of their viru-
lence program and avoid the innate microbicidal
functions of the macrophage.
Taking Aim at Surveillance Systems
Innate immune surveillance systems exist for the rapid
and non-specific detection of microbial invaders.
These systems operate on the basis of a limited reper-
toire of receptors whose ligands include specific
PAMPs — motifs associated with bacterial and viral
structural molecules and nucleic acids [1,39,40]. The
ingenuity of this system of surveillance stems from its
recognition of conserved and essential microbial
structures that are generally intolerant to changes that
might thereby reduce their recognition by PRRs.
Innate immune surveillance systems orchestrate
inflammatory reactions and the elaboration of inflam-
matory cytokines and antimicrobial molecules
intended to restrict growth and dissemination of
invading pathogens by alerting the cellular arm of the
immune system to their presence. The upstream
receptors of this innate surveillance system appear to
converge downstream on the pro-inflammatory tran-
scription factor, NF-κB, which normally remains
sequestered in the host cytoplasm bound to IκB.
Phosphorylation of IκB leads to its proteasome-
dependent degradation and the release of NF-κB for
translocation into the nucleus where it serves as a
ubiquitous transactivator of pro-inflammatory genes
such as interferon (IFN) γ, tumor necrosis factor (TNF)
α, interleukin-12 (IL-12), chemokines and cell adhesion
molecules [41,42] (Figure 2).
Extracellular Microbes: For Whom the Bell Tolls
One of the recently recognized classes of extracellu-
lar receptors involved in immune surveillance are the
Toll-like receptors (TLRs), the human homologues of
the Toll protein found in adult Drosophila [43–45].
Like Drosophila Toll, TLRs are type I transmembrane
proteins with an extracellular domain consisting of
several leucine-rich repeats (LRR), and a cytoplasmic
domain homologous to the cytoplasmic domain of
human IL-1, which serves as the site of intracellular
signal relay. Binding of ligands to TLRs results in the
rapid assembly of a membrane-proximal signaling
complex comprising the TLR cytoplasmic domain,
the adaptor protein MyD88, the serine/threonine
kinase IRAK (required for TLR signaling) and, in some
cases, a protein called Toll-interacting protein (Tollip)
[46], which has been shown to link IRAK to the IL-1
receptor during IL-1 signaling. Tollip is also known to
associate directly with TLR2 and TLR4 and inhibit
TLR-mediated responses by suppressing the phos-
phorylation and kinase activity of IRAK [47]. Together
with another negative regulator of TLR signaling,
IRAK-M [48], Tollip attenuates the pro-inflammatory
cytokine response downstream of TLR signaling and
thereby restores immune homeostasis following
TLR activation. 
These feedback mechanisms probably evolved to
prevent sustained TLR activation that would otherwise
lead to a pro-inflammatory cytokine bias that could
initiate the development of chronic inflammatory dis-
orders and autoimmune diseases, as observed during
the pathogenesis of Crohn’s disease [49]. Several
seminal papers have strengthened the importance of
TLR signaling through IRAK in the defense against
human diseases. TLR polymorphisms [50] and hered-
itary mutations in IRAK-4 [51,52] have been associ-
ated with recurrent infections by common bacteria
and increased susceptibility to pathogenic bacterial
infections, highlighting the importance of this surveil-
lance pathway in mounting proper inflammatory
responses against micro-organisms.
In addition to their presence on the surface of
cells, the plasticity of the TLR signaling pathways is
exemplified by compartmentalization of certain Toll
receptors [53,54] in a way that tailors the down-
stream immune pathway. For instance, TLR2 can
traffic to phagosomal membranes in response to
yeast and Gram-positive bacteria, but not Gram-neg-
ative bacteria [54], indicating that, at least in
macrophages, TLR can sample the contents of
phagocytic vacuoles and elicit an inflammatory
response appropriate to the invading microbe. This
level of specificity in TLR-mediated innate immune
responses could be important in the context of bac-
terial invasion into cells, whereby some pathogens
secrete type III or IV effectors to generate modified
invasion vacuoles or escape phagosomes altogether
to gain access to the cytoplasmic space, as is the
case for Listeria monocytogenes. 
It would seem feasible that TLR-dampening activi-
ties might be exploited by bacterial pathogens to
diminish TLR signaling. However, because virulence
proteins that mimic eukaryotic ones often arise by
convergent evolution, finding bacterial homologues (at
the nucleotide or amino acid level) of negative regula-
tors of TLR signaling might be difficult. Instead, iden-
tifying a functionally equivalent bacterial protein that
can antagonize the signaling cascade downstream of
TLR and IRAK might be better accomplished through
genetic and proteomic screens looking for bacterial
proteins that interact directly with these surveillance
receptors and their associated signaling molecules.
Many of the PAMPs that stimulate TLR signaling
have been elucidated, including lipopolysaccharide
(LPS), which is specific for TLR4, bacterial flagellin
(TLR5), CpG DNA (TLR9) and lipoteichoic acid (TLR2)
found predominantly in the cell wall of Gram-positive
bacteria. In the case of TLR4, it has been noted that
lipid A, the pro-inflammatory component of bacterial
LPS, varies in its acylation state and that this can alter
how TLR4 responds to LPS. Miller and co-workers
have shown that both P. aeruginosa [55] and Salmo-
nella enterica serovar Typhimurium [56] modify their
lipid A acylation state, thereby changing the stimula-
tory activity of this lipid in response to recognition by
TLR4. For instance, deacylation of lipid A by Salmo-
nella in response to the host environment decreases
its ability to induce TLR4-mediated NF-κB activation
[56], whereas conversion of penta-acylated lipid A in
P. aeruginosa to hexa-acylated lipid A makes the LPS
more inflammatory [57]. The generation of a more
stimulatory LPS in P. aeruginosa appears to be par-
tially offset by the ability of hexa-acylated lipid A to
resist damage by cationic antimicrobial peptides [55].
Although this mechanism of immune system avoid-
ance does not rely specifically on proteins secreted
from the bacteria, it is an important avoidance mech-
anism that acts in concert with other secreted effector
proteins whose collaborative effect is to ensure host
adaptation aimed at avoiding recognition by the
immune system. The recent discovery that phago-
some maturation in macrophages is regulated, in part,
by TLR4-dependent signals [58] and that eliminating
TLR-based signals impairs phagocytosis of various
pathogens makes it possible that several of the
pathogens that block their phagocytic uptake by
macrophages may do so by inhibiting an essential
TLR-dependent pathway.
Bacterial Hijacking of TLRs Can Manipulate the
Downstream Response
One of the more instructive examples of bacterially
induced attenuation of innate immune pathways
comes from the yersiniae literature. Y. pestis is the
causative organism of bubonic and pneumonic plague
and uses a type III secretion system for the transloca-
tion of effector molecules into target cells. Two other
related species, Y. pseudotuberculosis and Y. entero-
colitica, are food-borne pathogens that cause gas-
trointestinal diseases by using a similar type III
secretion system to manipulate the host. The type III
secretion system of yersiniae, encoded on a 70 kb vir-
ulence plasmid, is responsible for the anti-phagocytic
activity associated with bacterial attachment to
macrophages, by way of the translocated phosphoty-
rosine phosphatase called YopH (see above), which
disrupts the focal adhesions required for phagocyto-
sis [21,22,59]. The type III secretion system of Y.
pestis also secretes a protein known as low calcium
response V (LcrV). Both LcrV [60,61] and YopH [62]
have been shown to have anti-inflammatory properties
in vitro and in vivo, stimulating the elaboration of the
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anti-inflammatory cytokine IL-10 and suppressing the
production of IFNγ and TNF-α [61,63]. At least for Y.
pestis infection, this LcrV-induced IL-10 production is
critical for the dissolution of the immunological gran-
uloma, which aims to contain the infectious foci, even-
tually leading to systemic spread of the bacilli and
often fatal bacteremia [64].
Remarkably, Heesemann and colleagues [65]
recently demonstrated that LcrV-induced IL-10
immunosuppression is actually signaled though TLR2.
Paradoxically, the importance of this immunosup-
pressive effect for Yersinia pathogenesis (and the dis-
advantageous effect on the host) was underscored by
the observation that TLR2-deficient mice were actu-
ally less susceptible to oral infection with Y. enteroco-
litica than isogenic wild-type mice. It should be
emphasized that these categorical data describe a
novel ligand specificity for TLR2, since the binding of
secreted LcrV to TLR2 is independent of any PAMP
contained within LcrV itself. It appears then that LcrV
is a bona fide secreted virulence factor that alters the
outcome of innate immune signaling pathways to the
benefit of the pathogen by interacting directly with a
TLR. Of relevance, this mechanism of immune manip-
ulation is ostensibly not limited to those cells on which
the bacteria have attached, but rather could be
applied systemically to cells proximal and distal to the
site of infection. Recently, it was also demonstrated
that Candida albicans induces immunosuppression
through TLR2-derived signals that mediate increased
IL-10 production associated with a deleterious
immune response toward disseminated candidiasis
[66]. It would seem that exploiting IL-10 release via
TLR2 signaling is an important mechanism in the
pathogenesis of both fungal and bacterial infections.
Intracellular Bacteria Get the NOD
Recent studies have indicated the existence of a
second innate immune surveillance system that oper-
ates in the cytoplasm of host cells using protein
receptors called nucleotide-binding oligomerization
domain (NOD) proteins [67–69]. NOD receptors partic-
ipate in the identification of peptidoglycan from intra-
cellular bacteria and serve to perpetuate similar
pro-inflammatory signals to those generated by the
TLR family, except that the signals originating from
NOD proteins originate from a receptor–ligand
complex within the cytoplasm (Figure 2). NOD proteins
bear a striking resemblance in domain structure to a
family of plant disease resistance (R) proteins that
mediate resistance to plant pathogenic bacteria. 
NOD1 and NOD2 are important in the intracellular
recognition of bacteria by mammalian cells. These pro-
teins contain an amino-terminal caspase recruitment
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Figure 2. Targeting the surveillance
systems of innate immunity.
The innate immune response relies on sur-
veillance systems to detect foreign
microbes. Toll-like receptors (TLRs) are
pattern recognition receptors on the
surface of a variety of cell types that recog-
nize bacterial and viral proteins and nucleic
acids.  Currently there are 11 TLRs that
each have a distinct ligand specificity, but
can homodimerize and heterodimerize to
increase the repertoire of possible down-
stream signaling pathways. NODs on the
other hand are cytoplasmic detection
systems for peptidoglycan (PG), with NOD2
recognizing peptidoglycan from both
Gram-negative and Gram-positive bacteria
and NOD1 having a greater specificity for
Gram-negative peptidoglycan in particular.
The NF-κB signaling cascade is essential
for proper signaling downstream of both
TLR and NOD and its activation serves to
invoke a suite of pro-inflammatory media-
tors, such as cytokines, chemokines and
cell adhesion receptors. Yersinia secretes
a molecule called LcrV into the extracellu-
lar space that can bind directly to TLR2
and modify the downstream response in a
way that promotes the secretion of the
anti-inflammatory cytokine IL-10, while pre-
venting the widespread activation of pro-
inflammatory cytokines. Two other
secreted proteins, AvrA and YopJ, from
Salmonella and Yersinia, respectively,
directly interfere with the activation of NF-
κB. Bacterial interference with the
NOD–peptidoglycan detection system
could be possible through the use of addi-
tional secreted bacterial proteins (dotted































domain (or CARD) and multiple carboxy-terminal
leucine-rich repeats that mediate responsiveness to
bacterial peptidoglycan [70]. Recent work has identi-
fied the moieties present in peptidoglycan that are rec-
ognized by NOD1 and NOD2 — NOD2 recognizes a
conserved muramyldipeptide moiety present in the cell
wall of essentially all bacteria [71,72], whereas NOD1
appears to confer greater specificity for detection of
diaminopimelic acid present in the cell wall peptido-
glycan of Gram-negative bacteria [73,74]. 
Similar to TLR, the functional importance of NOD
signaling has been strengthened by the identification
of patients with nod mutations who are more suscep-
tible to chronic diseases with a bacterial etiology. In a
seminal paper, nod2 was described as the first sus-
ceptibility gene involved in the pathology of Crohn’s
disease [75]: a disease-associated frame-shift muta-
tion in the LRR domain of nod2 resulted in a NOD2
protein that no longer recognized peptidoglycan. At
present, bacterial proteins that antagonize the signal-
ing cascades directly proximal to NOD proteins have
not been described. However, modifying or dampen-
ing NOD-dependent signaling pathways might allow
intracellular pathogens a stealthy entry into host cells,
allowing them to evade detection and minimize the
pro-inflammatory reactions that would alert the
immune system to their presence. Members of the
Chlamydia species might even have adapted ways to
avoid NOD-based signaling altogether. For instance,
the ‘chlamydial anomaly’ is based on the observed
paradox that chlamydiae are sensitive to antibiotics
that inhibit peptidoglycan synthesis (like penicillin), yet
the organisms themselves do not make detectable
levels of peptidoglycan. This is further confounded by
the presence in the chlamydial genome of genes that
apparently encode products of the peptidoglycan syn-
thesis machinery. Could chlamydiae have evolved to
produce a modified peptidoglycan-like structure that
is not recognized by NODs? It is possible that NOD
receptors could be utilized as sensitive intracellular
detectors of peptidoglycan to sort out the chlamydial
anomaly, which is currently unresolved.
Recent data have shed light on the components
downstream of NOD proteins that contribute to
inflammatory signaling cascades. For example, upon
infection of HEK293 cells with Streptococcus pneu-
moniae it was demonstrated that NOD2 is required for
the downstream activation of NF-κB [76]. Interestingly,
by using dominant-negative constructs and small
inhibitory RNA, it was shown that the IL-1 receptor-
associated kinase 2 (IRAK2) was involved in NOD2-
dependent activation of NF-κB in response to
pneumococcal infection. This result is intriguing
because it represents the first report linking the mem-
brane-proximal IRAK family of kinases (associated
with TLR-dependent signaling) with the NOD signaling
pathway. Also in human colonic epithelial cells that
are poorly responsive to LPS, it has been shown that
constitutive expression of NOD1 plays an important
role in recognizing several enteric pathogens that
would normally bypass TLR signaling in the infected
epithelium [77]. Together these studies allude to a
functional interplay between TLR and NOD, which has
not yet been extensively investigated. Given that
secreted bacterial factors have been identified that
modulate TLR signaling cascades, the identification of
secreted virulence factors of intracellular organisms
that directly antagonize the function of NOD proteins
seems likely. 
Targeting the Converging Signals from TLRs and
NODs
As mentioned above, one of the common targets of
both TLR and NOD signaling is the pro-inflammatory
transcription factor NF-κB. Activation and nuclear
translocation of NF-κB in response to surveillance sig-
naling is necessary for the production of an appropri-
ate inflammatory response [78]. Not surprisingly, the
literature has become replete with examples of how
bacterial pathogens block or activate NF-κB for their
own advantage [3,79]. Two of the most well charac-
terized examples are YopJ and AvrA from Yersinia and
Salmonella, respectively, which achieve inhibition of
NF-κB following type III secretion into host cells. In
Yersinia, YopJ is a type-III-secreted effector that is
injected into the host cell cytoplasm following bacter-
ial attachment to the cell surface. Once injected, YopJ
binds to IκB kinase (IKK) to inhibit phosphorylation of
the NF-κB-inhibitory molecule IκB [80]. Blockade of
IκB phosphorylation in this manner prevents its ubiq-
uitination and effectively sequesters NF-κB in the
cytoplasm. Incidentally, YopJ has also been shown to
be a ubiquitin-like protein protease [81], indicating
that it may have multiple roles in inhibiting a variety of
mammalian signaling pathways. AvrA, a type-III-
secreted protein in Salmonella [82], has been shown
to inhibit NF-κB activation directly, although, unlike
YopJ, its mechanism of action involves inhibition
downstream of IKK phosphorylation [83].
The presence of YopJ/AvrA-related proteins in
plant pathogens such as AvrRBsT of Xanthamonas
campestris, as well as in a plant symbiont, Y4LO of
Rhizobium NGR234, suggests that this family of pro-
teins may play a fundamental role in pathogen–host
interactions, perhaps at the level of innate immune
subversion. Given that some secreted effectors
ostensibly appear to block NF-κB in a robust
manner, it would be constructive to investigate how
TLR- or NOD-dependent signaling is affected during
a natural infection with a microbe that targets NF-κB
specifically. Such experiments would address
whether the temporal and spatial expression and
delivery of virulence factors into the host is consis-
tent with the deactivation of TLR and NOD signaling
by the same pathogen.
Manipulating the Consequences of Innate Immune
Activation – Putting the Brakes on Immunity
Despite the myriad and elaborate ways in which bac-
terial pathogens use secreted proteins to avoid recog-
nition by the innate immune system, detecting and
responding appropriately to microbes is an unending
job of the immune sentinels. Even with the most
redundant of immune evasion strategies, activation of
immune surveillance systems during infection is
inevitable due to the functional plasticity of the
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immune cells involved. As such, the success of
pathogens that must live inside cells as inquilines is
often based on strategies to neutralize or modify the
downstream effect of innate immune activation, rather
than to avoid it altogether (Figure 3).
Abating the Signals Governing Adaptive Immunity
Some of the more extensively adapted of the human
pathogens are grouped within the chlamydiae, which
have caused human diseases since antiquity —
ancient Egyptian medical papyri point to the existence
of Chlamydia trachomatis infections. Chlamydiae are
obligate intracellular pathogens meaning that, akin to
viruses, invasion of a susceptible host cell is a pre-
requisite to initiation of their developmental cycle. As
obligate intracellular pathogens, chlamydiae are
exquisitely adapted for exploitation of their hosts,
which include both warm-blooded mammals and
several reptilian and amphibian species. In humans,
they give rise to the most prevalent bacterial sexually
transmitted disease and are the leading cause of
blindness in endemic areas of the world [84]. 
As with most intracellular infections, the cellular
immune response to Chlamydia infection is based on
antigen-specific major histocompatibility (MHC) class
I-restricted CD8+ cytotoxic T lymphocytes (CTLs) that
recognize and kill cells infected with bacteria. Indeed,
there are at least two reports demonstrating recogni-
tion by protective CD8+ CTLs of inclusion membrane-
associated proteins from C. trachomatis [85,86],
indicating that at least some chlamydial antigens are
recognized in the cytosol and are processed into pep-
tides for loading of MHC class I molecules. However,
the chronic nature of the diseases associated with
these organisms alludes to a mechanism involving a
modulation of the upstream pathways governing the
transition from innate to adaptive immunity. Interest-
ingly, Zhong and colleagues demonstrated the ability
of both C. trachomatis [87] and C. pneumoniae [88] to
degrade a host molecule called RFX5, a transcription
factor involved in the upstream activation of MHC
class I expression. This proteolytic activity was
dependent on a chlamydial protein, which they called
CPAF (for chlamydial protease-like activity factor), a
70 kDa heterodimeric protein secreted into the cyto-
plasm of infected host cells. RFX5 degradation was
inhibited by lactacystin, an irreversible proteasome
inhibitor, and by depletion of CPAF with specific anti-
bodies. In addition, this same group has demon-
strated the ability of the CPAF protease to interfere
with MHC class II expression on the surface of
infected cells [89]. Chlamydial inhibition of MHC class
II expression involved degradation of upstream stim-
ulatory factor 1 (USF-1), a constitutively expressed
transcription factor required for expression of class II
transactivator (CIITA), which is in turn required for IFN-
γ-inducible MHC class II expression. 
Because these experiments were carried out in
epithelial cell lines, it would be germane to study the
ability of chlamydiae to inhibit surface expression of
MHC class I and II molecules in professional APCs, as
it is these cells that would ultimately prime a naïve
immune system to the infection. While it has yet to be
determined just how CPAF is introduced into the cyto-
plasm of infected host cells, it was demonstrated to
be exclusively cytoplasmic in infected host cells and
not present in purified chlamydial organisms. It is pos-
sible that CPAF is a type-III-secreted substrate,
translocated directly into the cytoplasm across the
inclusion membrane, since these pathogens have the
core genetic components to assemble a type III secre-
tion system. With the use of heterologous bacterial
systems with tractable genetics, determining whether
CPAF is a type III substrate should be achievable. 
Helicobacter pylori is another human pathogen
that modulates the transition from innate to adaptive
immune responses. H. pylori is primarily an extracel-
lular pathogen that colonizes the human gastric
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Figure 3. Pathogen interference in the
innate to adaptive immune transition. 
Some bacterial pathogens can interfere
with the signals downstream of innate
immune activation that are required for
the generation of an adaptive immune
response. Chlamydia, for example,
secretes a protein called CPAF into the
cytoplasm of cells — this protein is a pro-
tease that degrades transcription factors
required for the expression of MHC class
I and II (MHC-I and MHC-II) molecules. H.
pylori VacA inhibits the activation of
helper T cells by blocking the loading of
MHC class II molecules and by preventing
T-cell receptor signaling. Other bacterial
secreted effectors (dotted lines) might
interfere with the processing and loading
of exogenous protein antigens onto MHC
class I molecules during a process called
cross-presentation, or usurp the function
of the host proteasome to their own





























mucosae and uses a type IV secretion system
encoded in the cag pathogenicity island to interact
with host cells. Pathogenicity islands are chromoso-
mal clusters of virulence genes, often unique to a
given pathogen. The ability of various H. pylori
strains to cause more severe gastric disease corre-
lates with the presence of a secreted toxin, called
vacuolating cytotoxin A (VacA) [90] encoded within
the cag pathogenicity island. In addition to its role in
disrupting tight junctions in the gastric epithelium,
VacA blocks the activation of clonal T cells by inter-
fering with antigen presentation within prelysosomal
compartments and by antagonizing T-cell receptor
signaling. Molinari et al. [91] showed that VacA inter-
feres with the proteolytic processing of tetanus toxin
and inhibits antigen presentation on newly synthe-
sized MHC class II molecules, while others demon-
strated that VacA inhibits antigen-dependent
proliferation of clonal T lymphocytes by interfering
with T-cell receptor signaling [92,93]. This latter
inhibitory mechanism works at the level of nuclear
factor of activated T cells (NFAT), a ubiquitous tran-
scriptional regulator of immune response genes. As
a result of NFAT inhibition by VacA, activation of key
pro-inflammatory cytokines such as IL-2 fails to take
place. The inhibition of T-cell activation may allow H.
pylori to establish its gastric niche and may help
account for the chronic nature of the disease associ-
ated with this organism.
Antimicrobial Peptides — a Difficult Challenge for
Microbes
Cationic antimicrobial peptides are expressed at
mucosal sites where the initial defense against invad-
ing bacteria takes place [94,95]. For example, human
defensin 5 (HD-5) is an antimicrobial polypeptide
expressed by Paneth cells, specialized epithelial cells
at the base of small intestinal crypts [96]. In Paneth
cells, antibiotic peptides are produced and stored in
secretory granules, which can be released quickly in
response to infection. An important functional study
examining the in vivo role of HD-5 was undertaken
using transgenic mice that overexpress HD-5 in
Paneth cells of the intestinal crypts [97]. In this model
system, HD-5 transgenic mice were more resistant to
oral infection with Salmonella enterica serovar
Typhimurium, clearly demonstrating that Paneth cell
defensins contribute to mucosal host defense against
infectious enteric disease.
The canonical model of how antimicrobial peptides
work involves the interaction of the peptide with the
outer membrane of prokaryotic cells, which tends to
be composed of negatively charged phospholipids.
The near neutral charge of eukaryotic outer mem-
branes is thought to be the basis of specificity of
antimicrobial peptides toward prokaryotic membranes.
The binding of the peptide to the outer membrane
induces lipid displacement and catastrophic alteration
of membrane structure, leading to microbicidal effects
on target cells. In addition to these activities on the
surface of target bacteria, antimicrobial peptides have
alternative functions in bridging innate and adaptive
immunity. For example, the α- and β- family of human
defensins have chemotactic activity for immature den-
dritic cells, peripheral blood T cells, neutrophils and
monocytes [98,99] and other antimicrobial peptides
have adjuvant properties that enhance cellular and
humoral immune responses [100].
Counteracting the activity of antimicrobial peptides
poses a special problem for invading bacteria,
because these peptides target fundamental properties
of the bacterial outer membrane that are difficult to
alter. Also, counteractive strategies involving the
secretion of proteins to neutralize antimicrobial pep-
tides are problematic for bacteria because the major-
ity of cationic peptides described are generally devoid
of unique consensus sequences that a secreted
protein might require for degradation or neutralization
of the antimicrobial peptide. The various structural
classes of antimicrobial peptides produced in
response to an infection also present a challenge for
invading bacteria. Probably for these reasons, there
are few examples of secreted bacterial proteins that
directly counteract the activity of cationic peptides.
Nevertheless, recent data may indicate that certain
bacteria may have indeed developed strategies to
overcome these obstacles. For example, S. flexneri is
able to decrease the expression of HD-1 and the
antimicrobial peptide LL-37 in colonic epithelial cell
lines and in biopsy tissues from the human colon
[101], although this activity was later recapitulated
with purified plasmid DNA from Shigella, and not a
secreted bacterial factor per se. 
Other circumstantial evidence exists that secreted
bacterial proteins from Salmonella might be involved
in downregulating microbicidal peptide production in
Paneth cells in mouse intestine. It was reported that
oral inoculation of mice with wild-type Salmonella
enterica serovar Typhimurium decreased the expres-
sion of cryptdins (the mouse counterpart of human α-
defensins), while a Salmonella mutant defective for the
type III secretion of Salmonella pathogenicity island-1
virulence factors lacked this inhibitory activity [102].
Perhaps more directly, others have demonstrated that
staphylokinase, a proteolytic exotoxin produced and
secreted by Staphylococcus aureus, induced the
extracellular release of α-defensins from polymor-
phonuclear cells, yet was then able to form a direct
complex with these peptides to completely neutralize
their microbicidal activity [103]. It remains to be seen
to what degree these aforementioned strategies for
dealing with cationic peptides actually contribute to
the pathogenesis of these organisms during a natural
infection. However, it seems that at least some
microbes have made antimicrobial peptides a target
of their ‘anti-immunity’ arsenal.
Moderating the Function of the Host Proteasome 
The eukaryotic proteasome performs many physio-
logical roles inside cells, such as regulation of the cell
cycle, processing of certain transcription factors, and
controlling protein turnover. With reference to the
immune system, the proteasome is responsible for the
degradation of microbial proteins and is the main
provider of peptide antigens for MHC class I presen-
tation (Figure 3). Of relevance, it has been shown that
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direct interaction with model colonic epithelia by non-
pathogenic Salmonella attenuates NF-κB-dependent
synthesis of inflammatory cytokines (namely IL-8) nor-
mally elicited by pro-inflammatory stimuli [104]. These
authors demonstrated that mucosal tolerance to non-
pathogenic enteric bacteria was mediated by an inhi-
bition of IκB degradation, which prevented nuclear
translocation of NF-κB. Although IκB was phosphory-
lated in response to intestinal microflora, polyubiquiti-
nation of IκB did not occur, and thus it was not a
substrate for the 26S proteasome. The authors sug-
gested that the ability of the bacteria–epithelial cell
interaction to induce an anti-inflammatory response
might be due to the delivery of a secreted bacterial
factor that either reduces the activity of the IκB ubiq-
uitin ligase directly or increases a specific de-ubiqui-
tinating activity. 
Brumell and co-workers [105] have also demon-
strated a relationship between bacterial pathogens in
the cytosol of macrophages and the ubiquitin–protea-
some system. In this work, Salmonella enterica
serovar Typhimurium that escaped invasion vacuoles
were polyubiquitinated in the cytosol and their growth
was constrained by recruitment of the proteasome to
the bacterial surface. Cytosolic growth restriction
occurred in macrophage cell lines, but not in epithelial
cells, suggesting that the cytosol of certain cell types
is differentially permissive for bacterial growth [106].
In support of this observation is the finding that a Sal-
monella enterica serovar Typhimurium mutant that
lacks the type-III-secreted effector SifA is unable to
stabilize the bacterial vacuole and is consequently
released into the cytosol of infected host cells. Sub-
sequently, the cytosolic bacteria are able to replicate
to at least wild-type levels in epithelial cells [107] but
are growth-restricted in macrophages [108]. It is pos-
sible that certain APCs have developed alternative
mechanisms of cytosolic surveillance involving the
ubiquitin–proteasome system that would put pressure
on intracellular pathogenic bacteria that escape into
the cytosol. Indeed, chemical inhibition of the protea-
some promoted the cytosolic replication of Salmonella
in macrophages, where it was normally growth-
restricted [105]. However, it is not known whether the
use of proteasome inhibitors might affect other host
cell functions related to antimicrobial effector function.
Could some bacterial pathogens secrete virulence
factors into the host macrophage that interfere or
modify ubiquitination and proteasome activity
directly? Based on the work of Neish et al. [104] dis-
cussed above, this hypothesis seems highly probable.
Such a strategy might give intravacuolar bacteria that
escape into the cytosol a chance to breach the host
cell and gain access to the extracellular space. It
might also have the added advantage of limiting NF-
κB activation and inflammatory reactions that also
require proteasome activity.
Uropathogenic and meningitis-causing E. coli use
a different mechanism to exploit the function of the
proteasome by secreting a toxin called cytotoxic
necrotizing factor 1 (CNF1). CNF1 specifically deami-
dates a glutamine residue in RhoA, Rac and Cdc42
into a glutamic acid, which abrogates the GTPase
activity of these proteins and renders them constitu-
tively active [109,110]. Paradoxically, CNF1-mediated
activation of these GTPases promotes their ubiquiti-
nation and degradation by the proteasome [111]. This
cycling of GTPase activation followed by degradation
of the activated Rho proteins helps to confer a highly
invasive phenotype to uropathogenic E. coli. Also,
because the activation of Rho-family GTPases can
induce an intrinsic host defense program, it has been
suggested that ubiquitin-mediated proteasomal
degradation of activated Rho proteins in response to
CNF1 intoxication may restrict the magnitude of the
host immune response seen during infection with
uropathogenic and meningitis-causing E. coli [112].
This is an intriguing example of how a secreted bac-
terial virulence factor achieves both invasion and
immune dampening by indirectly commandeering the
host cell proteasomal machinery. Although currently
there are no reports describing secreted bacterial
effectors that directly modulate the activity of the pro-
teasome, the idea that this system may somehow
constitute an innate surveillance system that bacter-
ial pathogens might usurp is a provocative hypothe-
sis — one that has been substantiated already for
various viral pathogens [113,114].
Perspectives
Within the past decade, there has been remarkable
progress made in our understanding of both innate
responses and bacterial effectors. The recent con-
vergence of these fields has resulted in a rapidly
expanding knowledge of these processes, and more
importantly, disease mechanisms. It has forced
microbiologists to learn cell biology and immunology,
and immunologists to appreciate the breadth and
strategies of microbial pathogens. It is also providing
a plethora of molecules that can be used as tools to
further probe innate response mechanisms. The
number of recently discovered bacterial effectors is
increasing very rapidly, and the task of identifying
host cellular targets lags significantly. Within the next
few years, as knowledge in both fields continues to
expand, our knowledge of how pathogens exploit
innate responses will grow tremendously. More
importantly, this information can be applied to under-
standing microbial diseases. The ability to modulate
innate responses to overcome pathogens to treat
microbial infections is a very attractive concept [115].
However, given that microbes are genetically very
promiscuous and constantly exchanging virulence
factors, it is likely that they will continue to evolve
new combinations of virulence factors to bypass
innate responses, resulting in new emerging infec-
tious diseases. Understanding the complex interac-
tions that occur between microbial pathogens and
their hosts that result in disease remains a lofty goal
of cellular microbiology. It is hoped we will eventually
understand enough to develop new therapies to
counter these microbial threats.
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